Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivani MedicalSTU:U5P -6.40%35 PB Ratio is 6.36 as of Sep. 09, 2026. GuruFocus rates STU:U5P with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,215 Biotechnology companies, Vivani Medical ranks worse than 76.79% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-09), Vivani Medical's share price is €1.17. Vivani Medical's Book Value per Share for the quarter that ended in Jun. 2026 was €0.18. Hence, Vivani Medical's PB Ratio of today is 6.36.
The historical rank and industry rank for Vivani Medical's PB Ratio or its related term are showing as below:
STU:U5P'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 6.37
Current: 6.37
During the past 6 years, Vivani Medical's highest PB Ratio was 6.37. The lowest was 0.00. And the median was 0.00.
STU:U5P's PB Ratio is ranked worse than 76.79% of 1215
companies
in the Biotechnology industry
Industry Median: 2.99
vs STU:U5P: 6.37
During the past 12 months, Vivani Medical's average Book Value Per Share Growth Rate was -30.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -38.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 45.40% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Vivani Medical was 120.40% per year. The lowest was -38.20% per year. And the median was 82.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vivani Medical PB Ratio Related Terms
Vivani Medical PB Ratio Historical Data
* Premium members only.
The historical data trend for Vivani Medical's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vivani Medical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivani Medical PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vivani Medical's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vivani Medical's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Vivani Medical's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vivani Medical (STU:U5P) has a PB Ratio of 6.36 as of Sep. 09, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vivani Medical and its competitors. According to the industry distribution chart, Vivani Medical ranks #933 out of 1215 companies in the Biotechnology industry, placing it in the top 76.8%.
Is Vivani Medical's PB Ratio too high?
Vivani Medical's current PB Ratio is 6.36. The Biotechnology industry median PB Ratio is 2.99. Vivani Medical's value of 6.36 is 112.7% above this industry median. Based on the distribution chart, Vivani Medical ranks #933 out of 1215 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vivani Medical has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Vivani Medical's PB Ratio compare to BDTX and VTVT?
According to the Biotechnology industry distribution chart, Vivani Medical ranks #933 out of 1215 companies for PB Ratio. This places Vivani Medical in the lower half of its industry. The industry median PB Ratio is 2.99. Vivani Medical's value of 6.36 is 112.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.99, based on 1,215 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivani Medical's current PB Ratio of 6.36 is 112.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vivani Medical and its competitors. For the Biotechnology industry, the median PB Ratio is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivani Medical's current PB Ratio is 6.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivani Medical stock overvalued right now?
Vivani Medical (STU:U5P) has a current PB Ratio of 6.36. The current PB Ratio is 6.36 and 112.7% above the Biotechnology industry median of 2.99. Vivani Medical's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vivani Medical (STU:U5P), the current PB Ratio is 6.36 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
35GF Score
Get the complete analysis for STU:U5P
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:U5P has been successfully added to your 
